Dyax Corp. (NASDAQ:DYAX) released the extension of its ongoing Phase 1b clinical trial evaluating DX-2930 to comprises additional patients and dosing cohorts. Dyax is developing DX-2930, an investigational fully human monoclonal antibody inhibitor of plasma kallikrein, as a subcutaneous injection for prevention of hereditary angioedema or HAE attacks. Dyax Corp. (NASDAQ:DYAX) stock hit highest price at $12.53, beginning with a price of $12.21 to the closed at 12.41 by an advance of 0.98% with a day range of $12.14-$12.53. The total market capitalization remained 1.691 Billion, total volume of 911860 shares held in the session was surprisingly higher than its average volume of 1002.36 shares.AmerisourceBergen Corporation (NYSE:ABC) released that its BOD have surged the quarterly dividend rate by 23% to $0.29 a share from $0.235 a share. This quarterly dividend will be payable December 1, 2014, to stockholders of record at the close of business on November 17, 2014. On the other consideration, AmerisourceBergen Corporation (NYSE:ABC) begun last trade with a price of $86.495 and throughout the trading session climbed at $88.215. The day-trade ended with an increase of 1.48% to closed at $88.19.Sysco Corporation (NYSE:SYY) declared that its net earnings for the Q1 ended September 27, 2014 decreased to $278.81M from previous year's $285.59M, with EPS dropping to $0.47 from $0.48 in the previous year. However, adjusted EPS increased to $0.52 from $0.49 in the previous year. Shares of Sysco Corporation (NYSE:SYY) opened at $37.38 with 587.25 million outstanding shares and hit to its highest price of $37.48 during the day and finally closed at $37.36 by scoring -0.35%. In the whole session, it traded on volume of 2.8 Million shares, which turned higher than its average volume.